The reliability of our strategies can be supported by many previous laboratory-confirmed findings, as described in the above review of CT83. Moreover, some of our bioinformatics findings will probably facilitate further laboratory studies on CT83. For example, based on the CCLE-BRCA dataset, the majority of breast cancer cell lines were CT83-negative, even some TNBC cell lines (such as MDA-MB-453, HCC1187, and DU4475), which is quite helpful by guiding our choice of appropriate cell models. This evidence concerns the gene CT83 and breast cancer.